LAUSR

Heart failure with reduced ejection fraction (HFrEF) is a leading cause of death worldwide; thus, therapeutic improvements are needed. In vivo preclinical models are essential to identify molecular drug targets for future therapies. Transverse aortic constriction (TAC) is a well‐established model of HFrEF; however, highly experienced personnel are needed for the surgery, and several weeks of follow‐up are necessary to develop HFrEF. To this end, we aimed (i) to develop an easy‐to‐perform mouse model of HFrEF by treating Balb/c mice with angiotensin‐II (Ang‐II) for 2 weeks by minipump and (ii) to compare its cardiac phenotype and transcriptome to the well‐established TAC model of HFrEF in C57BL/6J mice.